Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 30;13(1):16432.
doi: 10.1038/s41598-023-42444-z.

Alternative beliefs in psychedelic drug users

Affiliations

Alternative beliefs in psychedelic drug users

Alexander V Lebedev et al. Sci Rep. .

Abstract

Previous research has suggested that classical psychedelics can foster significant and enduring changes in personality traits and subjective wellbeing. Despite the lack of evidence for adverse effects on mental health stemming from psychedelic use, concerns persist regarding the capacity of these substances to modulate information processing and attitudes towards factual data. The aim of the present study was to investigate the propensity for accepting alternative facts and the general treatment of knowledge within a sample of 392 participants, 233 of whom reported at least a single incidence of psychedelic use in their lifetime. To do this, we leveraged step-wise methods of linear modelling investigating effects of demographics, psychiatric conditions and concomitant drug use. Our findings revealed a moderate positive association between psychedelic use and beliefs in alternative facts, as well as the specific belief that facts are politically influenced. However, no links were found for favouring intuition over evidence when confirming facts. Among other investigated drugs, only alcohol was negatively associated with beliefs in alternative facts. Taken together, our results support the link between psychedelic use and non-conformist thinking styles, which can be attributed to the psychological effects of the drugs themselves, but may also mirror a common trait related to unconventional beliefs and illicit substance use.

PubMed Disclaimer

Conflict of interest statement

The first author (AL) has assumed the position of Chief Executive Director at Katharsis Journeys Ltd. This role was undertaken after the submission of the manuscript and while the manuscript was under review. This international wellness company is dedicated to the provision of harm reduction services for individuals who engage in psychedelic experiences, with operations primarily located in the Netherlands. While this professional affiliation exists, it does not detract from the impartiality, objectivity, and academic rigor applied in the execution of this study and interpretation of its findings. The remaining co-authors have no conflict of interest to report. The authors reaffirm their commitment to the highest standards of research ethics, and any potential conflict of interest has been carefully managed to ensure the integrity of this study.

Figures

Figure 1
Figure 1
Coefficient plot of multiple regression models for the predictors of mean score on the CMQ. Estimate: non-standardized coefficients. Model1: minimal (psychedelic use and intercept), Model2: demographic adjustment, Model3: full model adjusted for concomitant drug use. Error bars denote 95% confidence intervals.
Figure 2
Figure 2
Differences in CMQ mean scores between psychedelic drug users and Non-Users. p/pcorrp-value, unadjusted and corrected for multiple testing: * < .05; ** < .01; *** < .001.
Figure 3
Figure 3
Coefficient plot of multiple regression models for the predictors of the EBS score: Truth Is Political. Model 1: minimal (psychedelic use and intercept), Model 2: demographic adjustment, Model 3: full model adjusted for concomitant drug use. Error bars denote 95% confidence intervals and *—p < .05; **—p < .01; ***—p < .001.
Figure 4
Figure 4
Differences in mean EBS scores between psychedelic drug users and non-users. FI-facts—Faith in intuition for facts. p/pcorrp-value, unadjusted and corrected for multiple testing: * < .05; ** < .01.
Figure 5
Figure 5
Cross-correlation network for the main investigated variables in a sample of psychedelic users (n = 180). Edges with numerical values represent Pearson correlation coefficients. The abbreviations used are as follows: CMQ—Conspiracy Mentality Questionnaire, EBSfFaith in intuition for facts, EBSeNeed for evidence, EBSpTruth is political; ALCp/f—temporal proximity and frequency of alcohol use, PSYp/f—temporal proximity and frequency of classical psychedelic use.

References

    1. Bogenschutz MP, et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J. Psychopharmacol. 2015;29:289–299. - PubMed
    1. Carhart-Harris RL, et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry. 2016;3:619–627. - PubMed
    1. Garcia-Romeu A, Griffiths R, Johnson M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr. Drug Abuse Rev. 2015;7:157–164. - PMC - PubMed
    1. Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 2015;29:57–68. - PubMed
    1. Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 2022;387:1637–1648. - PubMed

Publication types